Dr. Jeffrey Pinco Joins CyGene Laboratories as Medical Director.

CORAL SPRINGS, Fla. -- CyGene Laboratories, Inc. (OTC:CYGE) has named Dr. Jeffrey Pinco as its new medical director. CyGene, an innovative biotechnology company currently focused on predictive genomics, is preparing for the introduction of new diagnostic products. Dr. Pinco will lead a team dedicated to helping the company receive state and national laboratory accreditations to position CyGene for the launch of these products.

"Dr. Pinco is joining our team at a time when regulators are voicing concerns over direct-to-consumer sales of genetic profiling products by our industry," said Martin Munzer, CyGene's president and chief executive officer. "CyGene has always maintained very high standards and adhered to the strictest interpretation of the scientific method, and Dr. Pinco will help us continue that tradition of excellence."

Dr. Pinco served as the chief of the Department of Pathology at Fort Stewart Winn Army Hospital, and was responsible for all administrative and clinical aspects of the lab, including accreditation by the College of American Pathologists. He is a fellow of the college of American Pathology and is board certified in Anatomic and Clinical Pathology. He has conducted multiple lab inspections as the team leader. Dr. Pinco earned his medical degree from Mount Sinai medical school and a Bachelor in Engineering in Bioengineering from the University of Pennsylvania.

"From the beginning of our predictive genomic product development," explained Munzer, "CyGene has built a business model around the key elements that will make this industry a great value to the consumer and to society, by helping reduce healthcare costs. With help from Dr. Pinco, we will continue to set the standard for the industry by developing tools for the empowerment of consumers."

Dr. Pinco noted that: "CyGene's predictive genomic products are designed to encourage people to take proactive measures and improve their health through prevention. The company's intent in designing its forthcoming diagnostic products is to help people live longer, healthier lives by determining how they can address health issues that are critical to them. I look forward to working with Martin Munzer and the CyGene staff on these goals."

About CyGene Laboratories, Inc.

CyGene Laboratories Inc., based in Coral Springs, Florida, is a biotechnology company focused on commercializing genetic and diagnostic testing, as well as developing therapies for infectious, genetic and autoimmune diseases. CyGene's scientific base rests on its Haystack Processing technologies, which it has been developing since 1995. As a result of its work on Haystack Processing, the Company has achieved significant technological breakthroughs that have led to the discovery of its other platform technologies. CyGene believes its patented technologies have promise in the discovery, development and utilization of cutting edge diagnostics based on synthetic DNA and therapeutics based on the rapid clearance of pathogens from the blood.

About CyGeneDIRECT

CyGeneDIRECT is an online consumer website that provides individuals with education and the opportunity to decide whether genetic testing is right for them. Individuals are able to purchase genetic test kits from a third party fulfillment center and retrieve their results anonymously in a comprehensive personalized report available on a secure server. The reports help them to understand how their personal genetics affect certain risks, how other factors contribute in combination with their genetic profile, and how to modify these factors to decrease their risk. Each test report includes a technical report that allows consumer's to share their results with their physicians if they chose to do so. For more information on CyGeneDIRECT, please visit http://www.cygenedirect.com.

Forward-Looking Statements:

The statements made in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, when or whether the audits of our financial statements will be completed and audit opinions issued, due to unforeseen circumstances or unforeseen issues that may arise during the course of such audits. CyGene Laboratories Inc. has no duty and undertakes no obligation to update such statements. You should independently investigate and fully understand all risks before making investment decisions.